BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Visterra, Inc. 

One Kendall Square
Suite B3301
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-498-1070 Fax: 617-498-1073


SEARCH JOBS




Industry
Biotechnology






 Company News
Cambridge Biotech Visterra, Inc. Reels In $30 Million 10/2/2014 5:58:47 AM
Visterra, Inc. To Present Data At ICAAC On VIS513, Its Humanized Monoclonal Antibody That Targets A Conserved Site On The Dengue Virus E Protein 9/3/2014 11:05:35 AM
Visterra, Inc. To Present Data At ICAAC On VIS513, Its Humanized Monoclonal Antibody That Targets A Conserved Site On The Dengue Virus E Protein 9/3/2014 8:53:04 AM
Visterra, Inc. To Present At The 32nd Annual J.P. Morgan Healthcare Conference 1/13/2014 7:15:21 AM
Visterra, Inc. Acquires Exclusive Patent License For Monoclonal Antibodies Against Dengue Virus From Massachusetts Institute of Technology (MIT) 12/2/2013 9:21:39 AM
Visterra, Inc. Adds $8 Million, Ex-AMAG Pharmaceuticals, Inc. (AMAG) Execs, To Begin Clinical Push For Flu Antibody 12/2/2013 8:49:07 AM
Visterra, Inc. Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains With Pandemic Potential 9/13/2013 9:32:36 AM
Visterra, Inc. Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains With Pandemic Potential 9/9/2013 10:21:17 AM
Brian Pereira, M.D. is Named New CEO at Visterra, Inc. 7/15/2013 7:32:48 AM
Visterra, Inc. Boosts Series A to $26 Million, Adds Bill & Melinda Gates Foundation as Investor 11/9/2012 6:32:45 AM
12